VEGFA and metastatic malignant neoplasm: Bevacizumab (BV), a humanized recombinant monoclonal antibody against vascular endothelial growth factor (VEGF), was approved by the US food and drug administration (FDA) on the market based on its effectiveness in metastatic cancers.